Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Recent & Breaking News (NDAQ:TLPH)

AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries

PR Newswire August 29, 2016

12 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  August 15, 2016

AcelRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint

Benzinga.com  August 15, 2016

AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain

PR Newswire June 28, 2016

AcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes

PR Newswire June 27, 2016

AcelRx Pharmaceuticals to Participate in Three Upcoming Healthcare Investor Events in June

PR Newswire June 2, 2016

AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 following Ambulatory Abdominal Surgeries at Euroanaesthesia

PR Newswire May 26, 2016

New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140

PR Newswire May 24, 2016

AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type of Abdominal Surgery

PR Newswire May 6, 2016

AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May

PR Newswire May 4, 2016

AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results

PR Newswire May 2, 2016

AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016

PR Newswire April 28, 2016

AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016

PR Newswire March 29, 2016

AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics

PR Newswire March 25, 2016

AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study

PR Newswire March 14, 2016

AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results

PR Newswire March 7, 2016

AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain

PR Newswire March 7, 2016

AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016.

PR Newswire March 3, 2016

AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March

PR Newswire March 1, 2016

AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis

PR Newswire February 25, 2016